We sit down and talk to Dr. Abribat about Amolyt Pharma, which is developing therapeutic peptides to treat rare endocrine and metabolic diseases. The company recently announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its experimental therapeutic peptide, AZP-3601, for a life-altering rare disease called hypoparathyroidism. This is Amolyt’s first clinical trial as a company. The trial, being conducted at sites in Europe, will test whether AZP-3601 will benefit patients with hypoparathyroidism by restoring lasting levels of calcium in their blood. Thierry Abribat, PhD can discuss why therapeutic peptides may provide better treatment options for patients with rare endocrine and metabolic diseases, the unmet need in hypoparathyroidism, AZP-360 and the ongoing trial.
You can check out Amolyt Pharma Here: